In our previous work, we noticed decreasing levels of EZH2 in BRAFV600E-mutated melanoma cells treated with vemurafenib, while cells resistant to BRAF inhibitors showed an unchanged expression of EZH2 upon treatment with vemurafenib [48]. Here, EZH2 is linked to melanoma.